Clinical Characteristics and Prognosis of B-cell Acute Lymphoblastic Leukemia Patients with IKZF1 Deletion
10.19746/j.cnki.issn1009-2137.2025.04.006
- VernacularTitle:IKZF1缺失的急性B淋巴细胞白血病患者的临床特征及预后分析
- Author:
Li-Hua WANG
1
;
Yan GUO
1
;
Yuan ZHANG
1
;
Xiu-Feng WANG
1
;
Xian-Kai LIU
1
;
Yan HUANG
1
Author Information
1. 新乡医学院第一附属医院血液内科,新乡市淋巴瘤分子诊疗重点实验室,河南新乡 453100
- Publication Type:Journal Article
- Keywords:
B-cell acute lymphoblastic leukemia;
IKZF1 deletion;
clinical characteristics;
prognosis
- From:
Journal of Experimental Hematology
2025;33(4):966-971
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze clinical characteristics and prognosis of B-cell acute lymphoblastic leukemia(B-ALL)patients with IKZF1 deletion.Methods:72 patients with B-ALL admitted to our hospital from April 2020 to January 2023 were selected,IKZF1 deletion were detected,and clinical characteristics and prognosis were analyzed.Results:Among the 72 patients,a total of 32 patients(44.4％)were identified with IKZF1 deletions(IKZF1+).There was no statistically significant difference in basic clinical data between patients with normal IKZF1(IKZF1-)and those with IKZF1+(P＞0.05).The proportion of patients with IKZF1+in Ph+group was significantly higher than that in Ph-group(P＜0.05).The main types of IKZF1+were exon 1-8 deletion(34.4％)and exon 4-7 deletion(31.2％).The median OS and PFS of IKZF1-patients were significantly longer than those of IKZF1+patients(OS:26.0 months vs 16.0 months,x2=23.094,P＜0.05;PFS:26.0 months vs 16.0 months,x2=11.150,P＜0.05).Among IKZF1+patients,the median OS of patients who received allogeneic hematopoietic stem cell transplantation(allo-HSCT)was significantly longer than that of patients who did not receive allo-HSCT(no reached vs 15.0 months,x2=5.685,P＜0.05).Conclusion:IKZF1 deletion is a risk factor affecting the prognosis of B-ALL patients.
